Exmoor Pharma and Kincell Bio Announce Partnership to Offer Extensive Development and Manufacturing Services for Worldwide Cell and Gene Therapy Clients
Saturday, September 16, 2023
Exmoor Pharma and Kincell Bio have announced a new global partnership to offer a broad range of advanced therapy manufacturing services. This collaboration combines the strengths of both companies in cell and gene therapy (CGT) manufacturing across Europe and the United States, providing customers with access to a global development and manufacturing network and personalized customer-centric services.
Key highlights of this partnership include:
Comprehensive Capabilities: This partnership offers a suite of services for CGT developers in the U.S. and internationally, including:
-
Viral vector manufacturing
-
Autologous cell therapy production (e.g., CAR-T, CAR-NK, CAR-M, iPSC-derived)
-
Allogeneic cell therapy manufacturing (iPSC-derived and MSC)
-
Process and analytical development
-
Facility development consulting, leveraging eXmoor's extensive experience in designing over 30 CGT sites globally, enabling customers to bring manufacturing in-house seamlessly
-
CMC (Chemistry, Manufacturing, and Controls) development consulting, providing customers with a streamlined strategy for their clinical and commercial development.
Global Presence: Leveraging the networks and strategic locations of eXmoor and Kincell, this partnership aims to quickly enter global markets to meet the growing demand for cell and gene therapies.
State-of-the-Art Facilities: This collaboration is supported by advanced facilities, including eXmoor's 65,000 sq. ft Cell and Gene Therapy Centre in the UK and Kincell's 29,000 sq. ft. campus in Gainesville, Florida. These facilities enable vector production in the UK and the production of autologous and allogeneic cells in both the US and the UK.
Angela Osborne, CEO of eXmoor, commented, "We are addressing our customers' desire for specialized CGT CDMO expertise and personalized engagement while working with a single partner for global programs. Our partners will gain access to services typically associated with larger companies, such as launching cross-Atlantic clinical trials, without compromising the personalized attention each of our teams is known for."
Bruce Thompson, CEO of Kincell Bio, added, "We are excited to collaborate with eXmoor to support global opportunities. By seamlessly coordinating efforts across two different geographical regions, we will leverage our combined expertise to assist advanced therapy developers in addressing a wide range of manufacturing needs. This marks a period of growth for us, following our recent emergence from stealth mode. As we refocus our Gainesville team on manufacturing services, Kincell Bio remains committed to innovation. This will empower us to partner with clients across both regions, accelerating product development and providing therapeutic innovators with the best chances of bringing life-saving therapies to market."
